A method for evaluating treatment switching criteria in multiple sclerosis

Multiple Sclerosis

Volumn 16, Issue 12, 2010, Pages 1483-1489

  Healy, Brian C ^a   Glanz, Bonnie I ^a   Stankiewicz, James ^a   Buckle, Guy ^a   Weiner, Howard ^a   Chitnis, Tanuja ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

disease modifying therapies; multiple sclerosis; outcome measurement; relapsing remitting; treatment switching

Indexed keywords

BETA INTERFERON; GLATIRAMER; STEROID;

ADULT; ARTICLE; CLINICAL ASSESSMENT; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; EXPANDED DISABILITY STATUS SCALE; HAZARD RATIO; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; METHODOLOGY; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PROBABILITY; PROPORTIONAL HAZARDS MODEL; RECURRENCE RISK; RELAPSE; REMISSION; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; DRUG SUBSTITUTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MODELS, STATISTICAL; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES;

EID: 78650156742     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510379245     Document Type: Article

References (23)

1. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993 ; 43: 655-661.
2. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995 ; 45: 1268-1276.
3. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996 ; 39: 285-294.
4. Cohen BA, Khan O., Jeffery DR, et al. Identifying and treating patients with suboptimal responses. Neurology 2004; 63 (12 Suppl 6). S33-40.
5. Freedman MS, Cohen B., Dhib-Jalbut S., et al. Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command. Curr Med Res Opin 2009 ; 25: 2459-2470.
6. Gauthier SA, Glanz BI, Mandel M., et al. Incidence and factors associated with treatment failure in the CLIMB multiple sclerosis cohort study. J Neurol Sci 2009 ; 284: 116-119.
7. Carra A., Onaha P., Luetic G., et al. Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina. Eur J Neurol 2008 ; 15: 386-393.
8. Caon C., Din M., Ching W., Tselis A., Lisak R. and Khan O. Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis. Eur J Neurol 2006 ; 13: 471-474.
9. Zwibel HL Glatiramer acetate in treatment-naive and prior interferon-beta-1b-treated multiple sclerosis patients. Acta Neurol Scand 2006 ; 113: 378-386.
10. Gajofatto A., Bacchetti P., Grimes B., High A. and Waubant E. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing- remitting multiple sclerosis. Mult Scler 2009 ; 15: 50-58.
11. Gorman MP, Healy BC, Polgar-Turcsanyi M. and Chitnis T. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol 2009 ; 66: 54-59.
12. Kurtzke JF Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983 ; 33: 1444-1452.
13. Hernan MA and Robins JM Estimating causal effects from epidemiological data. J Epidemiol Community Health 2006 ; 60: 578-586.
14. Cox DR and Oakes D. Analysis of survival data. London, New York: Chapman and Hall, 1984.
15. Lunceford JK and Davidian M. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Stat Med 2004 ; 23: 2937-2960.
16. Hernan MA, Brumback B. and Robins JM Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000 ; 11: 561-570.
17. Efron B. and Tibshirani R. An Introduction to the Bootstrap. New York: Chapman & Hall, 1993.
18. Kurth T., Walker AM, Glynn RJ, et al. Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol 2006 ; 163: 262-270.
19. Team RDC. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2009.
20. Venables WN and Ripley BD Modern Applied Statistics with S, 4 th edn. New York: Springer, 2002.
21. Therneau T. and Lumley T. survival: Survival analysis, including penalised likelihood. R package version 2. 35-7. 2009. http://CRAN.R-project. org/package=survival.
22. Trojano M. Is it time to use observational data to estimate treatment effectiveness in multiple sclerosis? Neurology 2007 ; 69: 1478-1479.
23. Bang H. and Robins JM Doubly robust estimation in missing data and causal inference models. Biometrics 2005 ; 61: 962-973.